NCT03510663View on ClinicalTrials.gov

Phase I Study of OPC-61815

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

July 5, 2018

Study Completion Date

July 5, 2018

Conditions
Congestive Heart Failure
Interventions
DRUG

OPC-61815 16mg

OPC-61815 16mg will be intravenously administered once a week.

DRUG

OPC-61815 32mg

OPC-61815 32mg will be intravenously administered once a week.

DRUG

Moxifloxacin

400mg tablet will be administrated once a week.

DRUG

Placebos

Placebo will be intravenously administered once a week.

Trial Locations (1)

Unknown

Kyusyu Region, Fukuoka

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY